RDD Europe 2025, Co-Organized by Aptar Pharma and RDD Online, Celebrates 20 Years
Aptar Pharma, leader in respiratory drug delivery solutions, and RDD Online® are pleased to announce their co-organization of RDD® Europe 2025, which will be held in-person from Tuesday, May 6 to Friday, May 9, 2025 at the Estoril Congress Center in Estoril, Portugal.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250227163353/en/
RDD Europe 2025, Co-Organized by Aptar Pharma and RDD Online (Graphic: Business Wire)
Celebrating 20 years of RDD Europe and one of the largest and highly regarded international respiratory health conferences, RDD Europe 2025 will host over 500 scientists, engineers, clinicians and business professionals engaged in all aspects of nasal and pulmonary drug delivery.
With curated and peer reviewed content organized in six Knowledge Spaces, speakers, workshops, poster presenters and exhibitors will share timely, actionable insights under the following themes:
- Bench to Bedside: Emerging Therapies and Clinical Advances
- Inspiring Dry Powder Inhalation: Formulation Science and Device Design
- MDIs in Transition: Evolving Science and Regulations
- Advanced Inhalation: AI and Data Driven Design
- Aqueous Agenda: Soft Mist Inhalers and Nebulizer Advances
- Nasal Spotlight: Advances in Systemic and Nose-to-Brain Delivery.
Twelve delegate-selectable industry Workshops will take place on Wednesday, May 7, providing practical and interactive demonstrations of innovative technologies, products and capabilities in a small group setting.
An integrated Poster & Exhibition session will run throughout the 3-day conference, ensuring ample opportunity for networking, with 70 exhibit tables and 72 posters showcasing academic and industry research, and development breakthroughs across established and emerging nasal and pulmonary drug delivery platforms.
To complement in-person activities, RDD Europe 2025 will also include extended online access from April 29 to June 30, 2025 to on-demand presentations and company profiles. In addition, almost 3,000 peer-reviewed speaker and poster papers will be available to delegates for 12 months after the conference.
The conference will open with a Welcome Cocktail Reception on the evening of Tuesday, May 6, and Aptar Pharma will sponsor a Gala Dinner at a scenic location in Estoril on Thursday, May 8.
As a global leader in OINDP device design and technology, Aptar Pharma is proud to be a Co-Organizer of RDD Europe 2025 and will host a workshop on May 7. Entitled “Ready for Clinical Trials in 1 Hour: A Roadmap to Success,” this workshop will be co-presented by Jonathan Mulpas, Director Business Development Pulmonary Category, Aptar Pharma, Will Ganley, Manager, Computational Pharmaceutics, Nanopharm, an Aptar Pharma company, and Carolina Dantas, Head of Medical & Scientific Affairs, Pulmotree.
“Estoril is a great location to celebrate 20 years of RDD Europe conferences. I can’t wait to catch up with friends and organizations who have returned year after year since RDD Europe 2005 was first held in Paris,” commented Richard Dalby, one of the conference organizers. “So much has changed since then, and the innovation I’ve witnessed seems poised to have direct benefits on patient health, healthcare provider choice and environmental sustainability.”
Added Carolyn Penot, Director of Operational Marketing at Aptar Pharma, “RDD Europe 2025 is a must-attend event, and this year’s Knowledge Spaces will represent the latest thinking in nasal and pulmonary drug delivery. We look forward to celebrating 20 years of RDD Europe with our conference participants.”
To register as a delegate or learn more about sponsorship opportunities, visit the RDD Europe 2025 website.
About RDD Online
RDD Online manages the organization of Respiratory Drug Delivery conferences in the U.S., and partners with Aptar Pharma to run RDDevents in Europe and Asia. These international conferences, focused on technologies and solutions to improve patient health, routinely attract over 500 delegates from 25 countries representing academia, industry and regulatory agencies. RDD Online also supplies realistic mouth throat models, Nephele mixing inlets and dose collection tubes. We offer scientific and technical publications, web-based training, and a company directory of organizations active in pulmonary and nasal drug delivery. For more information, please visit www.rddonline.com.
About Aptar Pharma
Aptar Pharma is part of AptarGroup, Inc., a global leader in the design and manufacturing of a broad range of drug delivery, consumer product dispensing and active material science solutions and services. Aptar’s innovative solutions and services serve a variety of end markets including pharmaceutical, beauty, food, beverage, personal care and home care. Using insights, proprietary design, engineering and science to create dispensing, dosing and protective technologies for many of the world’s leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has approximately 13,000 dedicated employees in 20 countries. For more information, visit www.aptar.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250227163353/en/
Contacts
Media Contact
RDD Online, LLC
Richard Dalby
+1 (804) 239 1978
rdalby@rx.umaryland.edu
Media Contact
Aptar Pharma
Ciara Jackson
+49 1511 951 6502
ciara.jackson@aptar.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SLB Announces Debt Exchange Offer27.2.2025 13:50:00 EET | Press release
Schlumberger Limited (“SLB”) (NYSE: SLB) today announced that Schlumberger Holdings Corporation, an indirect wholly owned subsidiary of SLB (“SHC”), has commenced offers to exchange certain series of notes listed below (the “Existing SISA Notes”), issued by Schlumberger Investment S.A. (“SISA”), for up to $2,000,000,000 aggregate principal amount (such amount, as it may be amended, the “Maximum Exchange Amount”) of new notes listed below (the “New SHC Notes”), to be issued by SHC, and to be fully and unconditionally guaranteed on a senior unsecured basis by SLB. The offers to exchange each series of Existing SISA Notes for the corresponding series of New SHC Notes are collectively referred to herein as the “Offers.” The Offers are made upon the terms and subject to the conditions set forth in the exchange offer memorandum and consent solicitation statement, dated February 27, 2025 (as may be amended or supplemented from time to time, the “Exchange Offer Memorandum”). Capitalized terms
Compass Pathways Announces Fourth Quarter and Full-Year 2024 Financial Results and Business Highlights27.2.2025 13:30:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the fourth quarter and full year 2024 and provided an update on recent progress across its business. “We are excited that the first data readout from our pivotal phase 3 COMP360 program in treatment resistant depression continues on track with top-line 6-week data expected next quarter,” said Kabir Nath, Chief Executive Officer. “Building on last year’s promising phase 2a data in PTSD and the resources now available from the January financing, we are advancing plans to develop a late-stage clinical program for PTSD with the goal of getting COMP360 to patients as quickly as possible. The need for a new approach to treatment remains significant in TRD and PTSD and we believe COMP360 represents a novel treatment option in these mental health conditions.” Business Highlights The pivotal phase 3 clinical
Hansen and RiksTV Extend Partnership to Accelerate Customer Care and Billing Cloud Transformation Journey27.2.2025 13:00:00 EET | Press release
Hansen Technologies (ASX:HSN), a leading global provider of software and services to the communications, energy, and water industries, is pleased to announce that longtime customer RiksTV has extended its commitment to Hansen. Under the terms of the agreement, the company will upgrade and transform to the latest version of Hansen CCB in the cloud, part of the Hansen Suite for Communications, Technology & Media. As a result of this transformation, RiksTV, one of Norway’s leading pay-TV and streaming providers, will achieve greater business flexibility by moving from Oracle to a more flexible open-source solution. This is in line with the organisation’s cloud transformation journey via AWS. As a result of the transition, RiksTV expects to achieve a rapid ROI of 18 months on the transition – while placing them firmly on the path towards a cloud-native architecture. Hansen CCB provides flexible rating, billing, and customer care for communications and pay-TV service providers. Hansen CCB a
BeiGene Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates27.2.2025 13:00:00 EET | Press release
BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced financial results and corporate updates from the fourth quarter and full year 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250227911272/en/ (Graphic: Business Wire) “Our fourth quarter and full year results demonstrate our tremendous growth as a global oncology powerhouse, reinforced by the continued success of BRUKINSA and the development of one of the most prolific solid tumor pipelines in oncology with multiple data readouts expected this year,” said John V. Oyler, Co-Founder, Chairman, and CEO at BeiGene. “BRUKINSA is now the unequivocal leader in new CLL patient starts in the U.S., holds the broadest label of any BTK inhibitor and serves as the cornerstone of our hematology franchise, showing immense promise as a backbone alongside our late stage BCL2 inhibitor
Infobip Demonstrates How Network APIs are Driving Innovation at MWC27.2.2025 11:29:00 EET | Press release
At this year’s Mobile World Congress (MWC), global cloud communications platform Infobip is tapping into pioneering themes and activities spearheaded by the mobile industry association GSMA, highlighting how Network APIs drive innovation. Following several successful partnerships launching Camara-compliant Network APIs under the GSMA Open Gateway initiative, Infobip is at the forefront of helping telcos make the most of Network APIs. For instance, Infobip recently helped a major Brazilian operator to implement Number Verify (NV) and Silent Mobile Verification (SMV). This helps speed up verification while increasing conversion because there is less chance of user error. The new process also reduces the risks of fraud. The telecommunications company enhanced its onboarding process by integrating SMV into its engagement app, boosting conversion rates from 80% (using SMS-based OTP) to over 99%, ensuring seamless user validation for nearly 1.5 million monthly users. In addition, Infobip has
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom